Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Supernus Pharmaceuticals to merge with Indivior

PUBLIC · SUPNSep 09, 2026•about 2 hours ago

Acquiring Company

Supernus Pharmaceuticals

Acquired Company

Indivior

RockvilleGreater LondonBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareMedicalPharmaceutical

Description

Supernus Pharmaceuticals, Inc. is set to merge with Indivior to enhance its CNS portfolio. This merger aims to drive future growth and diversification by combining their innovative pipelines. The partnership will strengthen Supernus's position in the CNS market.

Company Information

Company

Supernus Pharmaceuticals

Location

Rockville, Maryland, United States

About

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company has a significant experience in CNS and has successfully introduced more than eight widely recognized products in this therapeutic category. Their recent advancement includes ONAPGO, a subcutaneous apomorphine infusion device for treating motor fluctuations associated with Parkinson’s disease. Supernus is committed to developing novel alternatives for managing neurological conditions.

Don't miss Supernus Pharmaceuticals's next move

Get an email the moment Supernus Pharmaceuticals makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Mollie
Senior decision-maker at this company
••••••••@••••••••

See Mollie's verified email →

Safet
Likely contact at this company
••••••••@••••••••

See Safet's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Supernus Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Indivior?

Indivior was acquired by Supernus Pharmaceuticals, based in Rockville. The deal was reported on September 9, 2026. Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus Pharmaceuticals is publicly traded (SUPN) and operates in Biotechnology.

When did Supernus Pharmaceuticals acquire Indivior?

Supernus Pharmaceuticals's acquisition of Indivior was reported on September 9, 2026. Supernus Pharmaceuticals, Inc. is set to merge with Indivior to enhance its CNS portfolio. This merger aims to drive future growth and diversification by combining their innovative pipelines. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Indivior do?

Indivior Pharmaceuticals, Inc. specializes in the treatment of addiction and is engaged in developing medicines to help individuals with substance use disorders. It is publicly traded (INDV), operating in Biotechnology, and is based in Greater London.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.